- About ELS
- Therapeutic Areas
- Operational Metrics
- Contact Us
Over 108 million people in India suffer from endocrine and metabolic disorders. Diabetes is the most prevalent disease in this therapeutic area with approximately 63 million cases in 2013. In 2011, nearly 9,83,000 deaths were reported to be caused due to diabetes, thereby making it the largest contributor to mortality. 78000 children are reported to develop type1 diabetes, every year.
As diabetes becomes a potential epidemic in India, this figure is likely to rise to 80 million by 2025 and by 2030, it is expected to cross the 100 million mark (one in every 10 adults), near twice as many as expected in China.
Our Principal Investigators see 400-500 new cases per month and approximately 2,000 recurrent cases per month. Some of their fields of expertise are diabetes, thyroid disorder, obesity and lipid disorders. Their research has been published in some of the country’s top medical journals including the National Medical Journal of India, Post Graduate Medical Journal and Journal of Association of Physicians of India (JAPI).
Among other metabolic disease, 42 million people in India suffer from thyroid diseases. As per a 2013 World Bank estimate, since the year 2000, there has been a steady 17% decline in fertility. Out of every 100 couples in India who visit the infertility clinics, the female is infertile in 50% cases, the male in 40% cases.
We ensure that metabolic and endocrine clinical trials are conducted according to ICH-GCP guidelines and meet the highest standards of ethics and integrity.